Arbutus Biopharma (ABUS) Equity Average: 2010-2025
Historic Equity Average for Arbutus Biopharma (ABUS) over the last 14 years, with Sep 2025 value amounting to $80.2 million.
- Arbutus Biopharma's Equity Average fell 30.07% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year decrease of 30.07%. This contributed to the annual value of $101.7 million for FY2024, which is 16.26% down from last year.
- Arbutus Biopharma's Equity Average amounted to $80.2 million in Q3 2025, which was down 1.08% from $81.1 million recorded in Q2 2025.
- Over the past 5 years, Arbutus Biopharma's Equity Average peaked at $167.6 million during Q1 2022, and registered a low of $80.2 million during Q3 2025.
- In the last 3 years, Arbutus Biopharma's Equity Average had a median value of $112.7 million in 2023 and averaged $110.4 million.
- Per our database at Business Quant, Arbutus Biopharma's Equity Average spiked by 55.14% in 2022 and then tumbled by 31.62% in 2025.
- Over the past 5 years, Arbutus Biopharma's Equity Average (Quarterly) stood at $149.8 million in 2021, then decreased by 5.74% to $141.2 million in 2022, then decreased by 20.19% to $112.7 million in 2023, then dropped by 9.36% to $102.1 million in 2024, then crashed by 30.07% to $80.2 million in 2025.
- Its Equity Average was $80.2 million in Q3 2025, compared to $81.1 million in Q2 2025 and $88.3 million in Q1 2025.